Methods of treating urea cycle disorders
OwnerBruce SCHARSCHMIDT, Masoud MOKHTARANIinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.
Claims20
A method of determining an effective dosage of a phenylacetic acid (PAA) prodrug for treating a urea cycle disorder in a subject in need thereof comprising:
- calculating a body surface area (BSA) for the subject;
- and
- comparing the BSA to a predetermined threshold value,
- wherein the effective dosage is a first dosage if the BSA is at or above the predetermined threshold value or a second dosage if the BSA is below the predetermined threshold value, and wherein the second dosage is higher than the first dosage as a function of BSA.
A method of evaluating compliance with a phenylacetic acid (PAA) prodrug treatment regimen in a subject with a urea cycle disorder (UCD) being treated with a PAA prodrug comprising:
- classifying the subject into a dosage group based on the dosage of a PAA prodrug the subject is currently receiving;
- determining a urinary phenylacetylglutamine (PAGN) level for the subject;
- and
- comparing the urinary PAGN level to a predetermined threshold urinary PAGN level,
- wherein a urinary PAGN level below the predetermined threshold urinary PAGN level indicates that the subject is non-compliant with the PAA prodrug treatment regimen.
A method of treating a urea cycle disorder (UCD) in a subject in need thereof comprising:
- classifying the subject into a body surface area (BSA) group based on the subject's BSA level;
- determining a urinary phenylacetylglutamine (PAGN) level for the subject;
- comparing the urinary PAGN level to a predetermined threshold urinary PAGN level;
- and
- administering a dosage of a PAA prodrug to the subject if the urinary PAGN level for the subject is below the predetermined threshold urinary PAGN level.
Dependencies are inferred from the claim text.